메뉴 건너뛰기




Volumn 37, Issue 6, 2015, Pages 1178-1194

Cardiometabolic Effects of a New Class of Antidiabetic Agents

Author keywords

cardiovascular; DPP 4; GLP 1 Agonists; SGLT 2; type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INCRETIN; LIPID; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; SODIUM GLUCOSE COTRANSPORTER 2;

EID: 84931010563     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.02.016     Document Type: Review
Times cited : (42)

References (95)
  • 1
    • 53749096863 scopus 로고    scopus 로고
    • 10-year follow-up of intensive glucose control in type 2 diabetes
    • R.R. Holman, S.K. Paul, and M.A. Bethel 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 15 2008 1577 1589
    • (2008) N Engl J Med , vol.359 , Issue.15 , pp. 1577-1589
    • Holman, R.R.1    Paul, S.K.2    Bethel, M.A.3
  • 2
    • 84907862963 scopus 로고    scopus 로고
    • Follow-up of blood-pressure lowering and glucose control in type 2 diabetes
    • S. Zoungas, J. Chalmers, and B. Neal Follow-up of blood-pressure lowering and glucose control in type 2 diabetes N Engl J Med 371 15 2014 1392 1406
    • (2014) N Engl J Med , vol.371 , Issue.15 , pp. 1392-1406
    • Zoungas, S.1    Chalmers, J.2    Neal, B.3
  • 3
    • 79956326006 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: Meta-analysis of randomized controlled trials
    • K. Esposito, D. Cozzolino, and G. Bellastella Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: Meta-analysis of randomized controlled trials Diabetes Obes Metab 13 7 2011 594 603
    • (2011) Diabetes Obes Metab , vol.13 , Issue.7 , pp. 594-603
    • Esposito, K.1    Cozzolino, D.2    Bellastella, G.3
  • 4
    • 84869217988 scopus 로고    scopus 로고
    • Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: Meta-analysis
    • H. Park, C. Park, Y. Kim, and K.L. Rascati Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: Meta-analysis Ann Pharmacother 46 11 2012 1453 1469
    • (2012) Ann Pharmacother , vol.46 , Issue.11 , pp. 1453-1469
    • Park, H.1    Park, C.2    Kim, Y.3    Rascati, K.L.4
  • 5
    • 79955728359 scopus 로고    scopus 로고
    • Predictors of response to dipeptidyl peptidase-4 inhibitors: Evidence from randomized clinical trials
    • M. Monami, F. Cremasco, and C. Lamanna Predictors of response to dipeptidyl peptidase-4 inhibitors: Evidence from randomized clinical trials Diabetes Metab Res Rev 27 4 2011 362 372
    • (2011) Diabetes Metab Res Rev , vol.27 , Issue.4 , pp. 362-372
    • Monami, M.1    Cremasco, F.2    Lamanna, C.3
  • 6
    • 84895467669 scopus 로고    scopus 로고
    • Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - A meta-analysis from randomized clinical trials
    • Y. Zhang, J. Hong, and J. Chi Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials Diabetes Metab Res Rev 30 3 2014 241 256
    • (2014) Diabetes Metab Res Rev , vol.30 , Issue.3 , pp. 241-256
    • Zhang, Y.1    Hong, J.2    Chi, J.3
  • 7
    • 77958030736 scopus 로고    scopus 로고
    • Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
    • A.J. Scheen, G. Charpentier, and C.J. Ostgren Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus Diabetes Metab Res Rev 26 7 2010 540 549
    • (2010) Diabetes Metab Res Rev , vol.26 , Issue.7 , pp. 540-549
    • Scheen, A.J.1    Charpentier, G.2    Ostgren, C.J.3
  • 8
    • 84877643773 scopus 로고    scopus 로고
    • A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: An example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus
    • J.L. Gross, J. Rogers, and D. Polhamus A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: An example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus BMJ Open 3 3 2013
    • (2013) BMJ Open , vol.3 , Issue.3
    • Gross, J.L.1    Rogers, J.2    Polhamus, D.3
  • 10
    • 84883765959 scopus 로고    scopus 로고
    • Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
    • B.M. Scirica, D.L. Bhatt, and E. Braunwald Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 14 2013 1317 1326
    • (2013) N Engl J Med , vol.369 , Issue.14 , pp. 1317-1326
    • Scirica, B.M.1    Bhatt, D.L.2    Braunwald, E.3
  • 11
    • 84883745765 scopus 로고    scopus 로고
    • Alogliptin after acute coronary syndrome in patients with type 2 diabetes
    • W.B. White, C.P. Cannon, and S.R. Heller Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 369 14 2013 1327 1335
    • (2013) N Engl J Med , vol.369 , Issue.14 , pp. 1327-1335
    • White, W.B.1    Cannon, C.P.2    Heller, S.R.3
  • 12
    • 84859174317 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: Systematic review and meta-analysis
    • T. Karagiannis, P. Paschos, and K. Paletas Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: Systematic review and meta-analysis BMJ 344 2012 e1369
    • (2012) BMJ , vol.344 , pp. e1369
    • Karagiannis, T.1    Paschos, P.2    Paletas, K.3
  • 13
    • 84865492997 scopus 로고    scopus 로고
    • Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus
    • H.R. Patil, F.J. Al Badarin, and H.A. Al Shami Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus Am J Cardiol 110 6 2012 826 833
    • (2012) Am J Cardiol , vol.110 , Issue.6 , pp. 826-833
    • Patil, H.R.1    Al Badarin, F.J.2    Al Shami, H.A.3
  • 14
    • 84871936025 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: A meta-analysis of randomized clinical trials
    • M. Monami, B. Ahren, I. Dicembrini, and E. Mannucci Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: A meta-analysis of randomized clinical trials Diabetes Obes Metab 15 2 2013 112 120
    • (2013) Diabetes Obes Metab , vol.15 , Issue.2 , pp. 112-120
    • Monami, M.1    Ahren, B.2    Dicembrini, I.3    Mannucci, E.4
  • 15
    • 84904007147 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: Meta-analysis of randomized clinical trials with 55,141 participants
    • S. Wu, I. Hopper, M. Skiba, and H. Krum Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: Meta-analysis of randomized clinical trials with 55,141 participants Cardiovasc Ther 32 4 2014 147 158
    • (2014) Cardiovasc Ther , vol.32 , Issue.4 , pp. 147-158
    • Wu, S.1    Hopper, I.2    Skiba, M.3    Krum, H.4
  • 16
    • 84878939138 scopus 로고    scopus 로고
    • Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus
    • W.B. White, R. Pratley, and P. Fleck Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus Diabetes Obes Metab 15 7 2013 668 673
    • (2013) Diabetes Obes Metab , vol.15 , Issue.7 , pp. 668-673
    • White, W.B.1    Pratley, R.2    Fleck, P.3
  • 17
    • 84912523371 scopus 로고    scopus 로고
    • Dipeptidyl-peptidase-4 inhibitors and heart failure: Class effect, substance-specific effect, or chance effect?
    • E. Standl, M. Erbach, and O. Schnell Dipeptidyl-peptidase-4 inhibitors and heart failure: Class effect, substance-specific effect, or chance effect? Curr Treat Options Cardiovasc Med 16 12 2014 353
    • (2014) Curr Treat Options Cardiovasc Med , vol.16 , Issue.12 , pp. 353
    • Standl, E.1    Erbach, M.2    Schnell, O.3
  • 18
    • 84901926135 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials
    • M. Monami, I. Dicembrini, and E. Mannucci Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials Nutr Metab Cardiovasc Dis 24 7 2014 689 697
    • (2014) Nutr Metab Cardiovasc Dis , vol.24 , Issue.7 , pp. 689-697
    • Monami, M.1    Dicembrini, I.2    Mannucci, E.3
  • 19
    • 84903315531 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors and cardiovascular safety
    • T.M. Davis Dipeptidyl peptidase-4 inhibitors and cardiovascular safety Med J Aust 200 8 2014 450 451
    • (2014) Med J Aust , vol.200 , Issue.8 , pp. 450-451
    • Davis, T.M.1
  • 20
    • 41849099939 scopus 로고    scopus 로고
    • Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension
    • G.C. Mistry, A.L. Maes, and K.C. Lasseter Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension J Clin Pharmacol 48 5 2008 592 598
    • (2008) J Clin Pharmacol , vol.48 , Issue.5 , pp. 592-598
    • Mistry, G.C.1    Maes, A.L.2    Lasseter, K.C.3
  • 21
    • 84855481995 scopus 로고    scopus 로고
    • Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: A pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
    • O.E. Johansen, D. Neubacher, and M. von Eynatten Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: A pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme Cardiovasc Diabetol 11 2012 3
    • (2012) Cardiovasc Diabetol , vol.11 , pp. 3
    • Johansen, O.E.1    Neubacher, D.2    Von Eynatten, M.3
  • 22
    • 77957231074 scopus 로고    scopus 로고
    • Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans
    • A. Marney, S. Kunchakarra, L. Byrne, and N.J. Brown Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans Hypertension 56 4 2010 728 733
    • (2010) Hypertension , vol.56 , Issue.4 , pp. 728-733
    • Marney, A.1    Kunchakarra, S.2    Byrne, L.3    Brown, N.J.4
  • 23
    • 79953217579 scopus 로고    scopus 로고
    • The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses
    • A. Ring, A. Port, and E.U. Graefe-Mody The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses Br J Clin Pharmacol 72 1 2011 39 50
    • (2011) Br J Clin Pharmacol , vol.72 , Issue.1 , pp. 39-50
    • Ring, A.1    Port, A.2    Graefe-Mody, E.U.3
  • 24
    • 84884198401 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients
    • M. Ayaori, N. Iwakami, and H. Uto-Kondo Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients J Am Heart Assoc 2 1 2013 e003277
    • (2013) J Am Heart Assoc , vol.2 , Issue.1 , pp. e003277
    • Ayaori, M.1    Iwakami, N.2    Uto-Kondo, H.3
  • 25
    • 84905858733 scopus 로고    scopus 로고
    • DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study
    • K. Nakamura, H. Oe, and H. Kihara DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study Cardiovasc Diabetol 13 1 2014 110
    • (2014) Cardiovasc Diabetol , vol.13 , Issue.1 , pp. 110
    • Nakamura, K.1    Oe, H.2    Kihara, H.3
  • 26
    • 34447267513 scopus 로고    scopus 로고
    • Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis
    • R.E. Amori, J. Lau, and A.G. Pittas Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis JAMA 298 2 2007 194 206
    • (2007) JAMA , vol.298 , Issue.2 , pp. 194-206
    • Amori, R.E.1    Lau, J.2    Pittas, A.G.3
  • 27
    • 79960019675 scopus 로고    scopus 로고
    • Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: Focus on incretins
    • S. Ansar, J. Koska, and P.D. Reaven Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: Focus on incretins Cardiovasc Diabetol 10 2011 61
    • (2011) Cardiovasc Diabetol , vol.10 , pp. 61
    • Ansar, S.1    Koska, J.2    Reaven, P.D.3
  • 28
    • 79951933599 scopus 로고    scopus 로고
    • Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes
    • A.J. Tremblay, B. Lamarche, and C.F. Deacon Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes Diabetes Obes Metab 13 4 2011 366 373
    • (2011) Diabetes Obes Metab , vol.13 , Issue.4 , pp. 366-373
    • Tremblay, A.J.1    Lamarche, B.2    Deacon, C.F.3
  • 29
    • 33746690405 scopus 로고    scopus 로고
    • Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
    • N. Matikainen, S. Manttari, and A. Schweizer Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes Diabetologia 49 9 2006 2049 2057
    • (2006) Diabetologia , vol.49 , Issue.9 , pp. 2049-2057
    • Matikainen, N.1    Manttari, S.2    Schweizer, A.3
  • 30
    • 84859463659 scopus 로고    scopus 로고
    • Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: A randomised double-blind placebo-controlled study
    • B. Eliasson, D. Moller-Goede, and K. Eeg-Olofsson Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: A randomised double-blind placebo-controlled study Diabetologia 55 4 2012 915 925
    • (2012) Diabetologia , vol.55 , Issue.4 , pp. 915-925
    • Eliasson, B.1    Moller-Goede, D.2    Eeg-Olofsson, K.3
  • 31
    • 34547660561 scopus 로고    scopus 로고
    • Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
    • B.J. Goldstein, M.N. Feinglos, and J.K. Lunceford Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes Diabetes Care 30 8 2007 1979 1987
    • (2007) Diabetes Care , vol.30 , Issue.8 , pp. 1979-1987
    • Goldstein, B.J.1    Feinglos, M.N.2    Lunceford, J.K.3
  • 32
    • 33846817233 scopus 로고    scopus 로고
    • Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial
    • M.A. Nauck, G. Meininger, and D. Sheng Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial Diabetes Obes Metab 9 2 2007 194 205
    • (2007) Diabetes Obes Metab , vol.9 , Issue.2 , pp. 194-205
    • Nauck, M.A.1    Meininger, G.2    Sheng, D.3
  • 33
    • 65549123794 scopus 로고    scopus 로고
    • Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial
    • M. Jadzinsky, A. Pfutzner, and E. Paz-Pacheco Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial Diabetes Obes Metab 11 6 2009 611 622
    • (2009) Diabetes Obes Metab , vol.11 , Issue.6 , pp. 611-622
    • Jadzinsky, M.1    Pfutzner, A.2    Paz-Pacheco, E.3
  • 34
    • 60249099791 scopus 로고    scopus 로고
    • Vildagliptin: A new oral treatment for type 2 diabetes mellitus
    • C. Mathieu, and E. Degrande Vildagliptin: A new oral treatment for type 2 diabetes mellitus Vasc Health Risk Manag 4 6 2008 1349 1360
    • (2008) Vasc Health Risk Manag , vol.4 , Issue.6 , pp. 1349-1360
    • Mathieu, C.1    Degrande, E.2
  • 35
    • 84857573175 scopus 로고    scopus 로고
    • Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide
    • S.N. Iyer, A.J. Drake 3rd, and R.L. West Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide Endocr Pract 18 1 2012 e10 e13
    • (2012) Endocr Pract , vol.18 , Issue.1 , pp. e10-e13
    • Iyer, S.N.1    Drake, A.J.2    West, R.L.3
  • 36
    • 84896731936 scopus 로고    scopus 로고
    • Pancreatic safety of incretin-based drugs - FDA and EMA assessment
    • A.G. Egan, E. Blind, and K. Dunder Pancreatic safety of incretin-based drugs - FDA and EMA assessment N Engl J Med 370 9 2014 794 797
    • (2014) N Engl J Med , vol.370 , Issue.9 , pp. 794-797
    • Egan, A.G.1    Blind, E.2    Dunder, K.3
  • 37
    • 18144401971 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
    • R.A. DeFronzo, R.E. Ratner, and J. Han Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 28 5 2005 1092 1100
    • (2005) Diabetes Care , vol.28 , Issue.5 , pp. 1092-1100
    • Defronzo, R.A.1    Ratner, R.E.2    Han, J.3
  • 38
    • 17144371646 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
    • D.M. Kendall, M.C. Riddle, and J. Rosenstock Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 28 5 2005 1083 1091
    • (2005) Diabetes Care , vol.28 , Issue.5 , pp. 1083-1091
    • Kendall, D.M.1    Riddle, M.C.2    Rosenstock, J.3
  • 39
    • 34249891874 scopus 로고    scopus 로고
    • Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
    • D. Kim, L. MacConell, and D. Zhuang Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes Diabetes Care 30 6 2007 1487 1493
    • (2007) Diabetes Care , vol.30 , Issue.6 , pp. 1487-1493
    • Kim, D.1    Macconell, L.2    Zhuang, D.3
  • 40
    • 83655184782 scopus 로고    scopus 로고
    • Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: A meta-analysis of the liraglutide clinical trial programme
    • B. Zinman, W.E. Schmidt, and A. Moses Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: A meta-analysis of the liraglutide clinical trial programme Diabetes Obes Metab 14 1 2012 77 82
    • (2012) Diabetes Obes Metab , vol.14 , Issue.1 , pp. 77-82
    • Zinman, B.1    Schmidt, W.E.2    Moses, A.3
  • 41
    • 62449169287 scopus 로고    scopus 로고
    • Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
    • M. Nauck, A. Frid, and K. Hermansen Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study Diabetes Care 32 1 2009 84 90
    • (2009) Diabetes Care , vol.32 , Issue.1 , pp. 84-90
    • Nauck, M.1    Frid, A.2    Hermansen, K.3
  • 42
    • 84922392829 scopus 로고    scopus 로고
    • Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes
    • L. Kuritzky, G. Umpierrez, and J.M. Ekoe Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes Postgrad Med 126 6 2014 60 72
    • (2014) Postgrad Med , vol.126 , Issue.6 , pp. 60-72
    • Kuritzky, L.1    Umpierrez, G.2    Ekoe, J.M.3
  • 43
    • 84908099303 scopus 로고    scopus 로고
    • Albiglutide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
    • J.M. Trujillo, and W. Nuffer Albiglutide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes Ann Pharmacother 48 11 2014 1494 1501
    • (2014) Ann Pharmacother , vol.48 , Issue.11 , pp. 1494-1501
    • Trujillo, J.M.1    Nuffer, W.2
  • 44
    • 84899585635 scopus 로고    scopus 로고
    • Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): A randomised, open-label, multicentre, non-inferiority phase 3 study
    • R.E. Pratley, M.A. Nauck, and A.H. Barnett Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): A randomised, open-label, multicentre, non-inferiority phase 3 study Lancet Diabetes Endocrinol 2 4 2014 289 297
    • (2014) Lancet Diabetes Endocrinol , vol.2 , Issue.4 , pp. 289-297
    • Pratley, R.E.1    Nauck, M.A.2    Barnett, A.H.3
  • 45
    • 84890360046 scopus 로고    scopus 로고
    • Lixisenatide as add-on therapy to basal insulin
    • D.X. Brown, E.L. Butler, and M. Evans Lixisenatide as add-on therapy to basal insulin Drug Des Devel Ther 8 2013 25 38
    • (2013) Drug des Devel Ther , vol.8 , pp. 25-38
    • Brown, D.X.1    Butler, E.L.2    Evans, M.3
  • 46
    • 79960777404 scopus 로고    scopus 로고
    • Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: A systematic review and meta-analysis
    • N.R. Pinelli, and K.M. Hurren Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: A systematic review and meta-analysis Ann Pharmacother 45 7-8 2011 850 860
    • (2011) Ann Pharmacother , vol.45 , Issue.7-8 , pp. 850-860
    • Pinelli, N.R.1    Hurren, K.M.2
  • 47
    • 59449101432 scopus 로고    scopus 로고
    • Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial
    • A. Garber, R. Henry, and R. Ratner Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 373 9662 2009 473 481
    • (2009) Lancet , vol.373 , Issue.9662 , pp. 473-481
    • Garber, A.1    Henry, R.2    Ratner, R.3
  • 48
    • 56549107405 scopus 로고    scopus 로고
    • Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
    • H. Linnebjerg, S. Park, and P.A. Kothare Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes Regul Pept 151 1-3 2008 123 129
    • (2008) Regul Pept , vol.151 , Issue.1-3 , pp. 123-129
    • Linnebjerg, H.1    Park, S.2    Kothare, P.A.3
  • 49
    • 35748957503 scopus 로고    scopus 로고
    • The physiology of glucagon-like peptide 1
    • J.J. Holst The physiology of glucagon-like peptide 1 Physiol Rev 87 4 2007 1409 1439
    • (2007) Physiol Rev , vol.87 , Issue.4 , pp. 1409-1439
    • Holst, J.J.1
  • 50
    • 77955573674 scopus 로고    scopus 로고
    • Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial
    • R.M. Bergenstal, C. Wysham, and L. MacConell Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial The Lancet 376 9739 2010 431 439
    • (2010) The Lancet , vol.376 , Issue.9739 , pp. 431-439
    • Bergenstal, R.M.1    Wysham, C.2    Macconell, L.3
  • 51
    • 79955661908 scopus 로고    scopus 로고
    • DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes
    • T. Blevins, J. Pullman, and J. Malloy DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes J Clin Endocrinol Meta 96 5 2011 1301 1310
    • (2011) J Clin Endocrinol Meta , vol.96 , Issue.5 , pp. 1301-1310
    • Blevins, T.1    Pullman, J.2    Malloy, J.3
  • 52
    • 67649666737 scopus 로고    scopus 로고
    • Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
    • J.B. Buse, J. Rosenstock, and G. Sesti Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 9683 2009 39 47
    • (2009) Lancet , vol.374 , Issue.9683 , pp. 39-47
    • Buse, J.B.1    Rosenstock, J.2    Sesti, G.3
  • 53
    • 84855489636 scopus 로고    scopus 로고
    • Glucagon like peptide-1 receptor expression in the human thyroid gland
    • B. Gier, P.C. Butler, and C.K. Lai Glucagon like peptide-1 receptor expression in the human thyroid gland J Clin Endocrinol Metab 97 1 2012 121 131
    • (2012) J Clin Endocrinol Metab , vol.97 , Issue.1 , pp. 121-131
    • Gier, B.1    Butler, P.C.2    Lai, C.K.3
  • 54
    • 77950228684 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation
    • L. Bjerre Knudsen, L.W. Madsen, and S. Andersen Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation Endocrinology 151 4 2010 1473 1486
    • (2010) Endocrinology , vol.151 , Issue.4 , pp. 1473-1486
    • Bjerre Knudsen, L.1    Madsen, L.W.2    Andersen, S.3
  • 55
    • 84895787341 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials
    • M. Monami, I. Dicembrini, and C. Nardini Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials Diabetes Res Clin Pract 103 2 2014 269 275
    • (2014) Diabetes Res Clin Pract , vol.103 , Issue.2 , pp. 269-275
    • Monami, M.1    Dicembrini, I.2    Nardini, C.3
  • 56
    • 84899029163 scopus 로고    scopus 로고
    • Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: Systematic review and meta-analysis of randomised and non-randomised studies
    • L. Li, J. Shen, and M.M. Bala Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: Systematic review and meta-analysis of randomised and non-randomised studies BMJ 348 2014 g2366
    • (2014) BMJ , vol.348 , pp. g2366
    • Li, L.1    Shen, J.2    Bala, M.M.3
  • 57
    • 84872055241 scopus 로고    scopus 로고
    • A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity
    • M.H. Noyan-Ashraf, E.A. Shikatani, and I. Schuiki A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity Circulation 127 1 2013 74 85
    • (2013) Circulation , vol.127 , Issue.1 , pp. 74-85
    • Noyan-Ashraf, M.H.1    Shikatani, E.A.2    Schuiki, I.3
  • 58
    • 84860807487 scopus 로고    scopus 로고
    • Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia
    • J. Lonborg, H. Kelbaek, and N. Vejlstrup Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia Circ Cardiovasc Interv 5 2 2012 288 295
    • (2012) Circ Cardiovasc Interv , vol.5 , Issue.2 , pp. 288-295
    • Lonborg, J.1    Kelbaek, H.2    Vejlstrup, N.3
  • 59
    • 79952694840 scopus 로고    scopus 로고
    • Cardiovascular safety of exenatide BID: An integrated analysis from controlled clinical trials in participants with type 2 diabetes
    • R. Ratner, J. Han, and D. Nicewarner Cardiovascular safety of exenatide BID: An integrated analysis from controlled clinical trials in participants with type 2 diabetes Cardiovasc Diabetol 10 2011 22
    • (2011) Cardiovasc Diabetol , vol.10 , pp. 22
    • Ratner, R.1    Han, J.2    Nicewarner, D.3
  • 60
    • 76949099016 scopus 로고    scopus 로고
    • Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: A double-blind, placebo-controlled, randomized pilot study
    • A. Gill, B.J. Hoogwerf, and J. Burger Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: A double-blind, placebo-controlled, randomized pilot study Cardiovasc Diabetol 9 2010 6
    • (2010) Cardiovasc Diabetol , vol.9 , pp. 6
    • Gill, A.1    Hoogwerf, B.J.2    Burger, J.3
  • 61
    • 84879800350 scopus 로고    scopus 로고
    • Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: A meta-analysis of clinical trials
    • B. Wang, J. Zhong, and H. Lin Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: A meta-analysis of clinical trials Diabetes Obes Metab 15 8 2013 737 749
    • (2013) Diabetes Obes Metab , vol.15 , Issue.8 , pp. 737-749
    • Wang, B.1    Zhong, J.2    Lin, H.3
  • 62
    • 84873554686 scopus 로고    scopus 로고
    • Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis
    • L.E. Robinson, T.A. Holt, and K. Rees Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis BMJ Open 3 1 2013
    • (2013) BMJ Open , vol.3 , Issue.1
    • Robinson, L.E.1    Holt, T.A.2    Rees, K.3
  • 63
    • 84871825708 scopus 로고    scopus 로고
    • Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research
    • C. Irace, S. De Luca, and E. Shehaj Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research Diab Vasc Dis Res 10 1 2013 72 77
    • (2013) Diab Vasc Dis Res , vol.10 , Issue.1 , pp. 72-77
    • Irace, C.1    De Luca, S.2    Shehaj, E.3
  • 64
    • 84895762544 scopus 로고    scopus 로고
    • Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study
    • M. Rizzo, M. Chandalia, and A.M. Patti Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study Cardiovasc Diabetol 13 1 2014 49
    • (2014) Cardiovasc Diabetol , vol.13 , Issue.1 , pp. 49
    • Rizzo, M.1    Chandalia, M.2    Patti, A.M.3
  • 65
    • 84875385071 scopus 로고    scopus 로고
    • Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
    • E. Chiquette, P.P. Toth, and G. Ramirez Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers Vasc Health Risk Manag 8 2012 621 629
    • (2012) Vasc Health Risk Manag , vol.8 , pp. 621-629
    • Chiquette, E.1    Toth, P.P.2    Ramirez, G.3
  • 66
    • 77953828230 scopus 로고    scopus 로고
    • DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks
    • J.B. Buse, D.J. Drucker, and K.L. Taylor DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks Diabetes Care 33 6 2010 1255 1261
    • (2010) Diabetes Care , vol.33 , Issue.6 , pp. 1255-1261
    • Buse, J.B.1    Drucker, D.J.2    Taylor, K.L.3
  • 67
    • 78851471129 scopus 로고    scopus 로고
    • Liraglutide - Overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes
    • M.J. Davies, R. Kela, and K. Khunti Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes Diabetes Obes Metab 13 3 2011 207 220
    • (2011) Diabetes Obes Metab , vol.13 , Issue.3 , pp. 207-220
    • Davies, M.J.1    Kela, R.2    Khunti, K.3
  • 68
    • 84883324640 scopus 로고    scopus 로고
    • Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
    • J. Rosenstock, D. Raccah, and L. Koranyi Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X) Diabetes Care 36 10 2013 2945 2951
    • (2013) Diabetes Care , vol.36 , Issue.10 , pp. 2945-2951
    • Rosenstock, J.1    Raccah, D.2    Koranyi, L.3
  • 69
    • 84904963065 scopus 로고    scopus 로고
    • HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin
    • B. Ahren, S.L. Johnson, and M. Stewart HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin Diabetes Care 37 8 2014 2141 2148
    • (2014) Diabetes Care , vol.37 , Issue.8 , pp. 2141-2148
    • Ahren, B.1    Johnson, S.L.2    Stewart, M.3
  • 70
    • 84919772916 scopus 로고    scopus 로고
    • HARMONY 4: Randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea
    • P.N. Weissman, M.C. Carr, and J. Ye HARMONY 4: Randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea Diabetologia 57 12 2014 2475 2484
    • (2014) Diabetologia , vol.57 , Issue.12 , pp. 2475-2484
    • Weissman, P.N.1    Carr, M.C.2    Ye, J.3
  • 71
    • 70350619609 scopus 로고    scopus 로고
    • Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study
    • A. Astrup, S. Rossner, and L. Van Gaal Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study Lancet 374 9701 2009 1606 1616
    • (2009) Lancet , vol.374 , Issue.9701 , pp. 1606-1616
    • Astrup, A.1    Rossner, S.2    Van Gaal, L.3
  • 72
    • 84908275752 scopus 로고    scopus 로고
    • SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes
    • R.G. Moses, S. Colagiuri, and C. Pollock SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes Australas Med J 7 10 2014 405 415
    • (2014) Australas Med J , vol.7 , Issue.10 , pp. 405-415
    • Moses, R.G.1    Colagiuri, S.2    Pollock, C.3
  • 73
    • 84882251091 scopus 로고    scopus 로고
    • Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis
    • D. Vasilakou, T. Karagiannis, and E. Athanasiadou Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis Ann Intern Med 159 4 2013 262 274
    • (2013) Ann Intern Med , vol.159 , Issue.4 , pp. 262-274
    • Vasilakou, D.1    Karagiannis, T.2    Athanasiadou, E.3
  • 74
    • 77953857048 scopus 로고    scopus 로고
    • Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial
    • C.J. Bailey, J.L. Gross, and A. Pieters Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial Lancet 375 9733 2010 2223 2233
    • (2010) Lancet , vol.375 , Issue.9733 , pp. 2223-2233
    • Bailey, C.J.1    Gross, J.L.2    Pieters, A.3
  • 75
    • 84888059660 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial
    • J.P. Wilding, G. Charpentier, and P. Hollander Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial Int J Clin Pract 67 12 2013 1267 1282
    • (2013) Int J Clin Pract , vol.67 , Issue.12 , pp. 1267-1282
    • Wilding, J.P.1    Charpentier, G.2    Hollander, P.3
  • 76
    • 84931008068 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy +/- oral agents in type 2 diabetes
    • Poster #764
    • D. Matthews, G. Fulcher, and V. Perkovic Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy +/- oral agents in type 2 diabetes European Association of Diabetes (EASD) 2012 Poster #764
    • (2012) European Association of Diabetes (EASD)
    • Matthews, D.1    Fulcher, G.2    Perkovic, V.3
  • 77
    • 84931007392 scopus 로고    scopus 로고
    • Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting
    • E.K. Buysman, W. Chow, H.J. Henk, and M.F. Rupnow Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting Curr Med Res Opin 2014 1 7
    • (2014) Curr Med Res Opin , pp. 1-7
    • Buysman, E.K.1    Chow, W.2    Henk, H.J.3    Rupnow, M.F.4
  • 78
    • 84901455931 scopus 로고    scopus 로고
    • Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
    • H.U. Haring, L. Merker, and E. Seewaldt-Becker Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial Diabetes Care 37 6 2014 1650 1659
    • (2014) Diabetes Care , vol.37 , Issue.6 , pp. 1650-1659
    • Haring, H.U.1    Merker, L.2    Seewaldt-Becker, E.3
  • 79
    • 84885952950 scopus 로고    scopus 로고
    • Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
    • H.U. Haring, L. Merker, and E. Seewaldt-Becker Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial Diabetes Care 36 11 2013 3396 3404
    • (2013) Diabetes Care , vol.36 , Issue.11 , pp. 3396-3404
    • Haring, H.U.1    Merker, L.2    Seewaldt-Becker, E.3
  • 80
    • 84866003015 scopus 로고    scopus 로고
    • Dapagliflozin monotherapy in drug-naive patients with diabetes: A randomized-controlled trial of low-dose range
    • C.J. Bailey, N. Iqbal, C. T'joen, and J.F. List Dapagliflozin monotherapy in drug-naive patients with diabetes: A randomized-controlled trial of low-dose range Diabetes Obes Metab 14 10 2012 951 959
    • (2012) Diabetes Obes Metab , vol.14 , Issue.10 , pp. 951-959
    • Bailey, C.J.1    Iqbal, N.2    T'Joen, C.3    List, J.F.4
  • 81
    • 84883810898 scopus 로고    scopus 로고
    • Urinary tract infections in patients with diabetes treated with dapagliflozin
    • K.M. Johnsson, A. Ptaszynska, and B. Schmitz Urinary tract infections in patients with diabetes treated with dapagliflozin J Diabetes Complications 27 5 2013 473 478
    • (2013) J Diabetes Complications , vol.27 , Issue.5 , pp. 473-478
    • Johnsson, K.M.1    Ptaszynska, A.2    Schmitz, B.3
  • 82
    • 84882290089 scopus 로고    scopus 로고
    • Genital mycotic infections in patients with diabetes
    • P. Nyirjesy, and J.D. Sobel Genital mycotic infections in patients with diabetes Postgrad Med 125 3 2013 33 46
    • (2013) Postgrad Med , vol.125 , Issue.3 , pp. 33-46
    • Nyirjesy, P.1    Sobel, J.D.2
  • 83
    • 84934288630 scopus 로고    scopus 로고
    • Safety profile of dapagliflozin for type 2 diabetes: Pooled analysis of clinical studies for overall safety and rare events
    • A. Ptaszynska, K.M. Johnsson, and S.J. Parikh Safety profile of dapagliflozin for type 2 diabetes: Pooled analysis of clinical studies for overall safety and rare events Drug Saf 37 10 2014 815
    • (2014) Drug Saf , vol.37 , Issue.10 , pp. 815
    • Ptaszynska, A.1    Johnsson, K.M.2    Parikh, S.J.3
  • 84
    • 84914689445 scopus 로고    scopus 로고
    • A safety evaluation of canagliflozin: A first-in-class treatment for type 2 diabetes
    • L.D. Boyle, and J.P. Wilding A safety evaluation of canagliflozin: A first-in-class treatment for type 2 diabetes Expert Opin Drug Saf 13 11 2014 1535 1544
    • (2014) Expert Opin Drug Saf , vol.13 , Issue.11 , pp. 1535-1544
    • Boyle, L.D.1    Wilding, J.P.2
  • 85
    • 84911028030 scopus 로고    scopus 로고
    • Sodium glucose transporter protein 2 inhibitors: Focusing on the kidney to treat type 2 diabetes
    • B. Peene, and K. Benhalima Sodium glucose transporter protein 2 inhibitors: Focusing on the kidney to treat type 2 diabetes Ther Adv Endocrinol Metab 5 5 2014 124 136
    • (2014) Ther Adv Endocrinol Metab , vol.5 , Issue.5 , pp. 124-136
    • Peene, B.1    Benhalima, K.2
  • 86
    • 84919681923 scopus 로고    scopus 로고
    • Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus
    • M.R. Weir, A. Januszewicz, and R.E. Gilbert Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus J Clin Hypertens (Greenwich) 16 12 2014 875 882
    • (2014) J Clin Hypertens (Greenwich) , vol.16 , Issue.12 , pp. 875-882
    • Weir, M.R.1    Januszewicz, A.2    Gilbert, R.E.3
  • 87
    • 84921936523 scopus 로고    scopus 로고
    • Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension
    • I. Tikkanen, K. Narko, and C. Zeller Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension Diabetes Care 2014
    • (2014) Diabetes Care
    • Tikkanen, I.1    Narko, K.2    Zeller, C.3
  • 88
    • 80155124676 scopus 로고    scopus 로고
    • Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
    • M.A. Nauck, S. Del Prato, and J.J. Meier Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 34 9 2011 2015 2022
    • (2011) Diabetes Care , vol.34 , Issue.9 , pp. 2015-2022
    • Nauck, M.A.1    Del Prato, S.2    Meier, J.J.3
  • 89
    • 84892488179 scopus 로고    scopus 로고
    • Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: Efficacy and safety over 2 years
    • J.P. Wilding, V. Woo, and K. Rohwedder Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: Efficacy and safety over 2 years Diabetes Obes Metab 16 2 2014 124 136
    • (2014) Diabetes Obes Metab , vol.16 , Issue.2 , pp. 124-136
    • Wilding, J.P.1    Woo, V.2    Rohwedder, K.3
  • 90
    • 84903792530 scopus 로고    scopus 로고
    • Empagliflozin as add on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM)
    • J. Rosenstock, A. Jelaska, and F. Wang Empagliflozin as add on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM) Can J Diabetes 2013 37
    • (2013) Can J Diabetes , pp. 37
    • Rosenstock, J.1    Jelaska, A.2    Wang, F.3
  • 91
    • 84884167643 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
    • W.T. Cefalu, L.A. Leiter, and K.H. Yoon Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial Lancet 382 9896 2013 941 950
    • (2013) Lancet , vol.382 , Issue.9896 , pp. 941-950
    • Cefalu, W.T.1    Leiter, L.A.2    Yoon, K.H.3
  • 92
    • 84892959743 scopus 로고    scopus 로고
    • The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
    • D.Z. Cherney, B.A. Perkins, and N. Soleymanlou The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus Cardiovasc Diabetol 13 2014 28
    • (2014) Cardiovasc Diabetol , vol.13 , pp. 28
    • Cherney, D.Z.1    Perkins, B.A.2    Soleymanlou, N.3
  • 93
    • 84903175006 scopus 로고    scopus 로고
    • Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes
    • J. Dziuba, P. Alperin, and J. Racketa Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes Diabetes Obes Metab 16 7 2014 628 635
    • (2014) Diabetes Obes Metab , vol.16 , Issue.7 , pp. 628-635
    • Dziuba, J.1    Alperin, P.2    Racketa, J.3
  • 94
    • 84892649479 scopus 로고    scopus 로고
    • Standards of medical care in diabetes - 2014
    • American Diabetes Association Standards of medical care in diabetes - 2014 Diabetes Care 37 suppl 1 2014 S14 S80
    • (2014) Diabetes Care , vol.37 , pp. S14-S80
  • 95
    • 84884550328 scopus 로고    scopus 로고
    • Rationale and design of the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE)
    • D.M. Nathan, J.B. Buse, and S.E. Kahn Rationale and design of the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE) Diabetes Care 36 8 2013 2254 2261
    • (2013) Diabetes Care , vol.36 , Issue.8 , pp. 2254-2261
    • Nathan, D.M.1    Buse, J.B.2    Kahn, S.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.